SEO Press Releases North Hollywood, CA, September 22, 2010 — According to an article posted on Sept. 3 in Infectious Disease News data was presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy showing the quadrivalent human papillomavirus vaccine (Gardasil) did not raise the risk for developing autoimmune conditions. The study was sponsored […]
To date, there have been 283 VAERS reports of abnormal Pap tests following HPV vaccination. Gardasil and Cervarix claim to offer protection against the most common HPV viruses associated with cervical cancer. What is wrong with this picture?
FOR IMMEDIATE RELEASE
PRLog (Press Release) – Sep 20, 2010 – Both FDA approved HPV vaccines, Gardasil and Cervarix, claim to offer protection from infections by the human papillomavirus genotypes most commonly associated with precancerous lesions and cervical cancer, HPV-16 and HPV-18. The manufacturers are also beginning to claim there is evidence of cross-protection against HPV genotypes 31 and 45. There are at least 283 young women who probably do not believe these statements.
The Vaccine Adverse Event Reporting System (VAERS) is a voluntary system. There are no requirements or legal obligations to report new medical conditions (adverse events) which occur after vaccination. Current estimates say that only 1-10% of the people who actually experience adverse events file reports.
The SaneVax team is concerned that with only 1-10% reporting, there may be as many as 28,300 people who have experienced abnormal Pap tests after HPV vaccination. This is not acceptable collateral damage.
MILFORD, Conn., Sep 20, 2010 (BUSINESS WIRE) — S.A.N.E. Vax, Inc. and Dr. Sin Hang Lee, on behalf of Milford Medical Laboratory, have agreed to offer a reliable human papillomavirus (HPV) genotyping test using a PCR system with short target DNA sequencing for safe vaccination practice.
Recognizing the alleged flaw in the two FDA-approved HPV tests, the National Cancer Institute (NCI) has awarded a contract to a Dutch diagnostic laboratory to perform “reliable genotyping using a PCR system with short target sequences” for the HPV isolated from biopsy samples collected in the NCI.
S.A.N.E. Vax, Inc. is a non-profit organization founded to promote safe, affordable, necessary and effective vaccines and vaccination practices. Dr. Lee said, “Milford Medical Laboratory will perform nested PCR with short target DNA sequencing for HPV genotyping on liquid-based cytology samples referred by S.A.N.E. Vax, Inc. at $50 per sample. Most health insurance companies will reimburse this cost.”
SEO Press Releases
North Hollywood, CA, September 13, 2010 — Norma Erickson, journalist for Examiner.com recently wrote an article about a 17 year-old from New Zealand adversely affected by Gardasil. Kahlia spent 2009 as a rotary exchange student in the United States as an active teen and an ambassador for her country. She had dreams and goals just like any adolescent girl her age. Those dreams came to a halt when Kahlia returned to New Zealand and had her first Gardasil injection.
A month later she was in the hospital. Just like other girls adversely affected by Gardasil, Kahlia had to withdraw from school. Her story is below:
On January 27, 2010, I had my first vaccination against cervical cancer. I started to experience headaches and nausea, which I did not relate to the vaccine at first. Over the next three weeks, I experienced uncontrollable mood swings, fatigue, insomnia, and clumsiness. I passed out a week before I was hospitalized.
On the night of February 27, I was hospitalized with tight, stabbing chest pains, shortness of breath, and headaches. My left leg had started spasming and I had a heavy feeling on my left side. After X-rays, ECG and blood tests all came back clear, I was sent home.
SANE Vax, Inc.
By: Norma Erickson
12 September 2010
The National Cancer Institute (NCI) announced on August 2, 2010 that it has awarded a $13.5 million contract to a Dutch diagnostic laboratory to perform reliable human papillomavirus (HPV) genotyping using a polymerase chain reaction (PCR) system with short target sequences for the cervical biopsy samples collected at the NCI.
Such reliable HPV genotyping technology was not used by the drug manufacturers in validating the efficacy of the genotype-specific HPV vaccines during the clinical trials required for Food and Drug Administration (FDA) approval, and has been rejected by the FDA for commercial distribution to clinical laboratories in the U.S. for general patient care.
This NCI contract confirms that the current FDA-approved HPV test kits for patient care in the U.S. are not reliable.
According to the pre-solicitation notice, HPV infections are very common in sexually active women and only a small subset progress to cervical cancer. When precancerous lesions appear, they may contain multiple types of HPV. It is difficult with the currently available FDA-approved HPV tests to determine whether the HPV strains present are responsible for causing the lesions, or simply there as a passenger.